ShareCompartir
Volume 14, Number 2—February 2008
Research
Cost-effectiveness of Human Papillomavirus Vaccination in the United States
Harrell W. Chesson*
, Donatus U. Ekwueme*, Mona Saraiya*, and Lauri E. Markowitz*
, Donatus U. Ekwueme*, Mona Saraiya*, and Lauri E. Markowitz*
Table 1
Estimated cost per QALY gained by adding routine HPV vaccination of 12-y-old girls to existing cervical cancer screening in the United States*
| Parameter | Population model |
Cohort model; no herd immunity, $US | |
|---|---|---|---|
| No herd immunity, $US | Herd immunity, $US | ||
| Excluding anal, vaginal, vulvar, and oropharyngeal cancers | |||
| Vaccine targets HPV types 6,11,16,18 | 10,294 | 5,336 | 8,593 |
| Vaccine targets HPV types 16,18 |
14,723 |
10,318 |
12,562 |
| Including anal, vaginal, vulvar, and orophayngeal cancers† | |||
| Vaccine targets HPV types 6,11,16,18 | 8,137 | 3,906 | 6,430 |
| Vaccine targets HPV types 16,18 | 11,602 | 7,848 | 9,471 |
*When applying base-case parameter values to 12 model variations. QALY, quality-adjusted life year; HPV, human papillomavirus.
†The oropharyngeal cancer sites we included were base of tongue, tonsillar, and other sites as described in the Technical Appendix.
- Page created: July 21, 2010
- Page last updated: July 21, 2010
- Page last reviewed: July 21, 2010
- Centers for Disease Control and Prevention,
-
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)